A dedicated official page offers PROTAC and partial-PROTAC synthesis, E3 ligand / linker design, molecular glues, ternary-complex and cellular degradation evaluation, and custom ADME/PK and toxicology services, through standalone or integrated projects.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A dedicated official page offers PROTAC and partial-PROTAC synthesis, E3 ligand / linker design, molecular glues, ternary-complex and cellular degradation evaluation, and custom ADME/PK and toxicology services, through standalone or integrated projects.
Offers formulation services from preclinical work through FIH and commercial supply, with publicly listed preformulation and oral solid and injectable dosage form development.
Program / service
Target / indication
Representative stage
Evidence & scope
PROTAC / molecular glue synthesis, biology, DMPK, and toxicology
Program-dependent / not disclosed · Determined by the collaboration program
Platform / services
This record does not claim platform-wide human validation
Formulation development / contract manufacturing capabilities
Defined by the client project · Defined by the client project
Services / platform
Service pages do not establish human evidence for every project
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Distinguish this company from related group entities developing proprietary drugs. This record refers only to Aurigene Pharmaceutical Services.
Available capacity, site-specific qualifications, project delivery history, pricing, and technology transfer terms require confirmation with the execution entity.
Company service pages support the stated scope but do not establish clinical validation of every dosage form or client program.
